Current therapy of small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC)

Abstract

In recent years, with the rapid development of molecular immunology and related biotechnology, immunotherapy has made breakthrough progress in tumor treatment. The main object of this paper is the current clinical treatment of different lung cancer and their advantages and disadvantages. Through the literature review method, the latest and most standard treatment methods were selected and summarized. Studies have found that chemotherapy, especially platinum-based chemotherapy, is still the most effective means for lung cancer in clinical practice, and immunotherapy mainly relies on combination with chemotherapy to play a role. However, as a new treatment method, epidemic therapy is becoming increasingly mature, and compared with traditional chemotherapy, it has greater research and development potential and broader prospects. The research and development of immunotherapy will be the focus of the therapies for lung cancer in the future. Researchers need to tailor treatment methods based on the principles of individualized treatment to optimize the design and outcomes of clinical studies.